Teva and Medincell’s schizophrenia drug meets main goal of late-stage study

(Reuters) -Israel-based Teva Pharmaceuticals and French partner Medincell said on Wednesday their injectable form of a schizophrenia drug had met its main goal in a late-stage study.

TEV-‘749, an under-the-skin version of a generic antipsychotic drug called olanzapine, met its main goal of reducing symptoms of schizeophrenia as measured along a widely used scale known as Positive and Negative Syndrome Scale (PANSS).

Symptoms for schizophrenia include delusions, hallucinations, disorganized speech, trouble with thinking and lack of motivation.

(Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath)